Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 191

1.

Back-to-Germline (B2G) Procedure for Antibody Devolution.

Schrade A, Bujotzek A, Spick C, Wagner M, Goerl J, Wezler X, Georges G, Kontermann RE, Brinkmann U.

Antibodies (Basel). 2019 Aug 26;8(3). pii: E45. doi: 10.3390/antib8030045.

2.

DuoMab: a novel CrossMab-based IgG-derived antibody format for enhanced antibody-dependent cell-mediated cytotoxicity.

Sustmann C, Dickopf S, Regula JT, Kettenberger H, Mølhøj M, Gassner C, Weininger D, Fenn S, Manigold T, Kling L, Künkele KP, Schwaiger M, Bossenmaier B, Griese JJ, Hopfner KP, Graff-Meyer A, Stahlberg H, Ringler P, Lauer ME, Brinkmann U, Schaefer W, Klein C.

MAbs. 2019 Nov-Dec;11(8):1402-1414. doi: 10.1080/19420862.2019.1661736. Epub 2019 Sep 17.

3.

Correction: DPH1 syndrome: two novel variants and structural and functional analyses of seven missense variants identified in syndromic patients.

Urreizti R, Mayer K, Evrony GD, Said E, Castilla-Vallmanya L, Cody NAL, Plasencia G, Gelb BD, Grinberg D, Brinkmann U, Webb BD, Balcells S.

Eur J Hum Genet. 2019 Apr 12. doi: 10.1038/s41431-019-0394-5. [Epub ahead of print]

PMID:
31477843
4.

DPH1 syndrome: two novel variants and structural and functional analyses of seven missense variants identified in syndromic patients.

Urreizti R, Mayer K, Evrony GD, Said E, Castilla-Vallmanya L, Cody NAL, Plasencia G, Gelb BD, Grinberg D, Brinkmann U, Webb BD, Balcells S.

Eur J Hum Genet. 2019 Mar 15. doi: 10.1038/s41431-019-0374-9. [Epub ahead of print] Erratum in: Eur J Hum Genet. 2019 Apr 12;:.

PMID:
30877278
5.

Highly flexible, IgG-shaped, trivalent antibodies effectively target tumor cells and induce T cell-mediated killing.

Dickopf S, Lauer ME, Ringler P, Spick C, Kern P, Brinkmann U.

Biol Chem. 2019 Jan 9. pii: /j/bchm.ahead-of-print/hsz-2018-0338/hsz-2018-0338.xml. doi: 10.1515/hsz-2018-0338. [Epub ahead of print]

PMID:
30864397
6.

Antibody-targeted chromatin enables effective intracellular delivery and functionality of CRISPR/Cas9 expression plasmids.

Killian T, Buntz A, Herlet T, Seul H, Mundigl O, Längst G, Brinkmann U.

Nucleic Acids Res. 2019 Jun 4;47(10):e55. doi: 10.1093/nar/gkz137.

7.

Highly flexible, IgG-shaped, trivalent antibodies effectively target tumor cells and induce T cell-mediated killing.

Dickopf S, Lauer ME, Ringler P, Spick C, Kern P, Brinkmann U.

Biol Chem. 2019 Feb 25;400(3):343-350. doi: 10.1515/hsz-2018-0338.

PMID:
30763031
8.

The Functional Role of Prostate Cancer Metastasis-related Micro-RNAs.

Weidle UH, Epp A, Birzele F, Brinkmann U.

Cancer Genomics Proteomics. 2019 Jan-Feb;16(1):1-19. doi: 10.21873/cgp.20108. Review.

9.

Effects of Ultrasonic Dispersion Energy on the Preparation of Amorphous SiO₂ Nanomaterials for In Vitro Toxicity Testing.

Wiemann M, Vennemann A, Stintz M, Retamal Marín RR, Babick F, Lindner GG, Schuster TB, Brinkmann U, Krueger N.

Nanomaterials (Basel). 2018 Dec 22;9(1). pii: E11. doi: 10.3390/nano9010011.

10.

Quantitative fluorescence imaging determines the absolute number of locked nucleic acid oligonucleotides needed for suppression of target gene expression.

Buntz A, Killian T, Schmid D, Seul H, Brinkmann U, Ravn J, Lindholm M, Knoetgen H, Haucke V, Mundigl O.

Nucleic Acids Res. 2019 Jan 25;47(2):953-969. doi: 10.1093/nar/gky1158.

11.

Engineering therapeutic bispecific antibodies using CrossMab technology.

Klein C, Schaefer W, Regula JT, Dumontet C, Brinkmann U, Bacac M, Umaña P.

Methods. 2019 Feb 1;154:21-31. doi: 10.1016/j.ymeth.2018.11.008. Epub 2018 Nov 16. Review.

12.

Importance of diphthamide modified EF2 for translational accuracy and competitive cell growth in yeast.

Hawer H, Ütkür K, Arend M, Mayer K, Adrian L, Brinkmann U, Schaffrath R.

PLoS One. 2018 Oct 18;13(10):e0205870. doi: 10.1371/journal.pone.0205870. eCollection 2018.

13.

Diphthamide affects selenoprotein expression: Diphthamide deficiency reduces selenocysteine incorporation, decreases selenite sensitivity and pre-disposes to oxidative stress.

Mayer K, Mundigl O, Kettenberger H, Birzele F, Stahl S, Pastan I, Brinkmann U.

Redox Biol. 2019 Jan;20:146-156. doi: 10.1016/j.redox.2018.09.015. Epub 2018 Sep 26.

14.

Interplay between reversible phosphorylation and irreversible ADP-ribosylation of eukaryotic translation elongation factor 2.

Mateus-Seidl R, Stahl S, Dengl S, Birzele F, Herrmuth H, Mayer K, Niederfellner G, Liu XF, Pastan I, Brinkmann U.

Biol Chem. 2019 Mar 26;400(4):501-512. doi: 10.1515/hsz-2018-0280.

PMID:
30218597
15.

Transcytosis of payloads that are non-covalently complexed to bispecific antibodies across the hCMEC/D3 blood-brain barrier model.

Schmid D, Buntz A, Hanh Phan TN, Mayer K, Hoffmann E, Thorey I, Niewöhner J, Vasters K, Sircar R, Mundigl O, Kontermann RE, Brinkmann U.

Biol Chem. 2018 Jun 27;399(7):711-721. doi: 10.1515/hsz-2017-0311.

PMID:
29466231
16.

Corrigendum to "Bispecific antibodies" [Drug Discov. Today 20 (July (7)) (2015) 838-847].

Kontermann RE, Brinkmann U.

Drug Discov Today. 2019 Jul;24(7):1422. doi: 10.1016/j.drudis.2017.12.004. Epub 2018 Jan 5. No abstract available.

PMID:
29309739
17.

The Role of micro RNAs in Breast Cancer Metastasis: Preclinical Validation and Potential Therapeutic Targets.

Weidle UH, Dickopf S, Hintermair C, Kollmorgen G, Birzele F, Brinkmann U.

Cancer Genomics Proteomics. 2018 Jan-Feb;15(1):17-39. Review.

18.

Disruption of diphthamide synthesis genes and resulting toxin resistance as a robust technology for quantifying and optimizing CRISPR/Cas9-mediated gene editing.

Killian T, Dickopf S, Haas AK, Kirstenpfad C, Mayer K, Brinkmann U.

Sci Rep. 2017 Nov 13;7(1):15480. doi: 10.1038/s41598-017-15206-x.

19.

Influence of DPH1 and DPH5 Protein Variants on the Synthesis of Diphthamide, the Target of ADPRibosylating Toxins.

Mayer K, Schröder A, Schnitger J, Stahl S, Brinkmann U.

Toxins (Basel). 2017 Feb 24;9(3). pii: E78. doi: 10.3390/toxins9030078.

20.

The making of bispecific antibodies.

Brinkmann U, Kontermann RE.

MAbs. 2017 Feb/Mar;9(2):182-212. doi: 10.1080/19420862.2016.1268307. Review.

21.

Characterization of a re-engineered, mesothelin-targeted Pseudomonas exotoxin fusion protein for lung cancer therapy.

Bauss F, Lechmann M, Krippendorff BF, Staack R, Herting F, Festag M, Imhof-Jung S, Hesse F, Pompiati M, Kollmorgen G, da Silva Mateus Seidl R, Bossenmaier B, Lau W, Schantz C, Stracke JO, Brinkmann U, Onda M, Pastan I, Bosslet K, Niederfellner G.

Mol Oncol. 2016 Oct;10(8):1317-29. doi: 10.1016/j.molonc.2016.07.003. Epub 2016 Jul 14.

22.

Anti-tumoral, anti-angiogenic and anti-metastatic efficacy of a tetravalent bispecific antibody (TAvi6) targeting VEGF-A and angiopoietin-2.

Scheuer W, Thomas M, Hanke P, Sam J, Osl F, Weininger D, Baehner M, Seeber S, Kettenberger H, Schanzer J, Brinkmann U, Weidner KM, Regula J, Klein C.

MAbs. 2016;8(3):562-73. doi: 10.1080/19420862.2016.1147640.

23.

Engineered hapten-binding antibody derivatives for modulation of pharmacokinetic properties of small molecules and targeted payload delivery.

Dengl S, Sustmann C, Brinkmann U.

Immunol Rev. 2016 Mar;270(1):165-77. doi: 10.1111/imr.12386. Review.

24.

Bispecific Antibodies for Targeted Delivery of Dendritic Polyglycerol (dPG) Prodrug Conjugates.

Mehrabadi FS, Adelmann J, Gupta S, Wedepohl S, Calderón M, Brinkmann U, Haag R.

Curr Cancer Drug Targets. 2016;16(7):639-49.

PMID:
26853135
25.

TriFabs--Trivalent IgG-Shaped Bispecific Antibody Derivatives: Design, Generation, Characterization and Application for Targeted Payload Delivery.

Mayer K, Baumann AL, Grote M, Seeber S, Kettenberger H, Breuer S, Killian T, Schäfer W, Brinkmann U.

Int J Mol Sci. 2015 Nov 17;16(11):27497-507. doi: 10.3390/ijms161126037.

26.

Acoustic Coordinated Reset Neuromodulation in a Real Life Patient Population with Chronic Tonal Tinnitus.

Hauptmann C, Ströbel A, Williams M, Patel N, Wurzer H, von Stackelberg T, Brinkmann U, Langguth B, Tass PA.

Biomed Res Int. 2015;2015:569052. doi: 10.1155/2015/569052. Epub 2015 Oct 19.

27.

Hapten-Binding Bispecific Antibodies for the Targeted Delivery of SiRNA and SiRNA-Containing Nanoparticles.

Thorey IS, Grote M, Mayer K, Brinkmann U.

Methods Mol Biol. 2016;1364:219-34. doi: 10.1007/978-1-4939-3112-5_18.

PMID:
26472454
28.

Loss of diphthamide pre-activates NF-κB and death receptor pathways and renders MCF7 cells hypersensitive to tumor necrosis factor.

Stahl S, da Silva Mateus Seidl AR, Ducret A, Kux van Geijtenbeek S, Michel S, Racek T, Birzele F, Haas AK, Rueger R, Gerg M, Niederfellner G, Pastan I, Brinkmann U.

Proc Natl Acad Sci U S A. 2015 Aug 25;112(34):10732-7. doi: 10.1073/pnas.1512863112. Epub 2015 Aug 10.

29.

Induction of heat shock protein HSPA6 (HSP70B') upon HSP90 inhibition in cancer cell lines.

Kuballa P, Baumann AL, Mayer K, Bär U, Burtscher H, Brinkmann U.

FEBS Lett. 2015 Jun 4;589(13):1450-8. doi: 10.1016/j.febslet.2015.04.053. Epub 2015 May 7.

30.

Bispecific antibodies.

Kontermann RE, Brinkmann U.

Drug Discov Today. 2015 Jul;20(7):838-47. doi: 10.1016/j.drudis.2015.02.008. Epub 2015 Feb 26. Review. Erratum in: Drug Discov Today. 2018 Jan 5;:.

31.

Hapten-directed spontaneous disulfide shuffling: a universal technology for site-directed covalent coupling of payloads to antibodies.

Dengl S, Hoffmann E, Grote M, Wagner C, Mundigl O, Georges G, Thorey I, Stubenrauch KG, Bujotzek A, Josel HP, Dziadek S, Benz J, Brinkmann U.

FASEB J. 2015 May;29(5):1763-79. doi: 10.1096/fj.14-263665. Epub 2015 Feb 10.

32.

Tumor-antigen-binding bispecific antibodies for cancer treatment.

Weidle UH, Kontermann RE, Brinkmann U.

Semin Oncol. 2014 Oct;41(5):653-60. doi: 10.1053/j.seminoncol.2014.08.004. Epub 2014 Aug 12. Review.

33.

Zirconium-89 labeled antibodies: a new tool for molecular imaging in cancer patients.

van de Watering FC, Rijpkema M, Perk L, Brinkmann U, Oyen WJ, Boerman OC.

Biomed Res Int. 2014;2014:203601. doi: 10.1155/2014/203601. Epub 2014 May 28. Review.

34.

A novel glycoengineered bispecific antibody format for targeted inhibition of epidermal growth factor receptor (EGFR) and insulin-like growth factor receptor type I (IGF-1R) demonstrating unique molecular properties.

Schanzer JM, Wartha K, Croasdale R, Moser S, Künkele KP, Ries C, Scheuer W, Duerr H, Pompiati S, Pollman J, Stracke J, Lau W, Ries S, Brinkmann U, Klein C, Umana P.

J Biol Chem. 2014 Jul 4;289(27):18693-706. doi: 10.1074/jbc.M113.528109. Epub 2014 May 19.

35.

Prospects of bacterial and plant protein-based immunotoxins for treatment of cancer.

Weidle UH, Tiefenthaler G, Schiller C, Weiss EH, Georges G, Brinkmann U.

Cancer Genomics Proteomics. 2014 Jan-Feb;11(1):25-38. Review.

PMID:
24633317
36.

The translational potential for target validation and therapy using intracellular antibodies in oncology.

Weidle UH, Maisel D, Brinkmann U, Tiefenthaler G.

Cancer Genomics Proteomics. 2013 Nov-Dec;10(6):239-50. Review.

PMID:
24336633
37.

Quantification of cell surface proteins with bispecific antibodies.

Panke C, Weininger D, Haas A, Schelter F, Schlothauer T, Bader S, Sircar R, Josel HP, Baer U, Burtscher H, Mundigl O, Grote M, Brinkmann U, Sustmann C.

Protein Eng Des Sel. 2013 Oct;26(10):645-54. doi: 10.1093/protein/gzt035. Epub 2013 Aug 19.

38.

The emerging role of new protein scaffold-based agents for treatment of cancer.

Weidle UH, Auer J, Brinkmann U, Georges G, Tiefenthaler G.

Cancer Genomics Proteomics. 2013 Jul-Aug;10(4):155-68. Review.

PMID:
23893924
39.

PK modulation of haptenylated peptides via non-covalent antibody complexation.

Hoffmann E, Konkar A, Dziadek S, Josel HP, Conde-Knape K, Kropp H, Kling L, Stubenrauch K, Thorey I, Dengl S, Brinkmann U.

J Control Release. 2013 Oct 10;171(1):48-56. doi: 10.1016/j.jconrel.2013.06.021. Epub 2013 Jun 22.

40.

A novel angiopoietin-2 selective fully human antibody with potent anti-tumoral and anti-angiogenic efficacy and superior side effect profile compared to Pan-Angiopoietin-1/-2 inhibitors.

Thomas M, Kienast Y, Scheuer W, Bähner M, Kaluza K, Gassner C, Herting F, Brinkmann U, Seeber S, Kavlie A, Welschof M, Ries S, Weidner KM, Regula JT, Klein C.

PLoS One. 2013;8(2):e54923. doi: 10.1371/journal.pone.0054923. Epub 2013 Feb 6.

41.

The intriguing options of multispecific antibody formats for treatment of cancer.

Weidle UH, Tiefenthaler G, Weiss EH, Georges G, Brinkmann U.

Cancer Genomics Proteomics. 2013 Jan-Feb;10(1):1-18. Review.

PMID:
23382582
42.

Targeted siRNA Delivery and mRNA Knockdown Mediated by Bispecific Digoxigenin-binding Antibodies.

Schneider B, Grote M, John M, Haas A, Bramlage B, Ickenstein LM, Jahn-Hofmann K, Bauss F, Cheng W, Croasdale R, Daub K, Dill S, Hoffmann E, Lau W, Burtscher H, Ludtke JL, Metz S, Mundigl O, Neal ZC, Scheuer W, Stracke J, Herweijer H, Brinkmann U.

Mol Ther Nucleic Acids. 2012 Sep 18;1:e46. doi: 10.1038/mtna.2012.39.

43.

Genetically engineered fusion proteins for treatment of cancer.

Weidle UH, Schneider B, Georges G, Brinkmann U.

Cancer Genomics Proteomics. 2012 Nov;9(6):357-72. Review.

PMID:
23162075
44.

Bispecific antibody derivatives with restricted binding functionalities that are activated by proteolytic processing.

Metz S, Panke C, Haas AK, Schanzer J, Lau W, Croasdale R, Hoffmann E, Schneider B, Auer J, Gassner C, Bossenmaier B, Umana P, Sustmann C, Brinkmann U.

Protein Eng Des Sel. 2012 Oct;25(10):571-80. Epub 2012 Sep 13.

45.

Progress in overcoming the chain association issue in bispecific heterodimeric IgG antibodies.

Klein C, Sustmann C, Thomas M, Stubenrauch K, Croasdale R, Schanzer J, Brinkmann U, Kettenberger H, Regula JT, Schaefer W.

MAbs. 2012 Nov-Dec;4(6):653-63. doi: 10.4161/mabs.21379. Epub 2012 Aug 27. Review.

46.

Generation of fluorescent IgG fusion proteins in mammalian cells.

Haas AK, Mayer K, Brinkmann U.

Methods Mol Biol. 2012;901:265-76. doi: 10.1007/978-1-61779-931-0_17.

PMID:
22723107
47.

Bispecific antibody derivatives based on full-length IgG formats.

Grote M, Haas AK, Klein C, Schaefer W, Brinkmann U.

Methods Mol Biol. 2012;901:247-63. doi: 10.1007/978-1-61779-931-0_16.

PMID:
22723106
48.

Fully human targeted cytotoxic fusion proteins: new anticancer agents on the horizon.

Weidle UH, Georges G, Brinkmann U.

Cancer Genomics Proteomics. 2012 May-Jun;9(3):119-33. Review.

PMID:
22593247
49.

Development of tetravalent IgG1 dual targeting IGF-1R-EGFR antibodies with potent tumor inhibition.

Croasdale R, Wartha K, Schanzer JM, Kuenkele KP, Ries C, Mayer K, Gassner C, Wagner M, Dimoudis N, Herter S, Jaeger C, Ferrara C, Hoffmann E, Kling L, Lau W, Staack RF, Heinrich J, Scheuer W, Stracke J, Gerdes C, Brinkmann U, Umana P, Klein C.

Arch Biochem Biophys. 2012 Oct 15;526(2):206-18. doi: 10.1016/j.abb.2012.03.016. Epub 2012 Mar 21.

PMID:
22464987
50.

Human-protein-derived peptides for intracellular delivery of biomolecules.

Haas AK, Maisel D, Adelmann J, von Schwerin C, Kahnt I, Brinkmann U.

Biochem J. 2012 Mar 15;442(3):583-93. doi: 10.1042/BJ20111973.

PMID:
22150630

Supplemental Content

Loading ...
Support Center